Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 25 от 154

Набира участници

Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance

Exercise Blood Pressure Vasodilation Vascular Function in Healthy Volunteers +2

Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance

Начало: 24.06.2025 Край: 30.03.2026 Възраст: 18–45 г. Друго

Australia Nuritas Ltd NCT06894875

Набира участници

Hypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA)

The goal of this interventional study is to assess the safety and performance of the XII Medical Hypoglossal Nerve Stimulation (HGNS) System in people who have moderate to severe Obstructive Sleep Apnea (OSA). Participation in this study involves being implanted with a Neurostimulator which provides electrical stimulation of the hypoglossal nerve (HGN). Participants will receive treatment at home during sleep, and participate in sleep studies to track and record the quality of the sleep. Participants will be monitored over the course of the study.

Начало: 24.06.2025 Край: 01.06.2029 Възраст: от 21 г. Устройства

Australia XII Medical NCT07049744

Набира участници Фаза 3

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

Allergy Peanut Allergy

The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.

Начало: 24.06.2025 Край: 01.05.2028 Възраст: 1–3 г. Лечение

Australia, Canada, France +5 DBV Technologies NCT07003919

Набира участници

A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia

Idiopathic Hypersomnia Narcolepsy Type 1 (NT 1) Narcolepsy Type 2 (NT2)

The aim of this project is to learn about how a change in diet will affect sleepiness, quality of life and metabolic health in people living with narcolepsy and idiopathic hypersomnia. The dietary changes we will be testing are well researched and safe in a wide range of patient groups (such as in obesity, type one and two diabetes, cancer and dysfunction related to the nervous system) but has not been researched in conditions of hypersomnolence such as narcolepsy and idiopathic hypersomnia. It is important to test adjunct therapies and lifestyle changes such as dietary interventions to ensure that people living with hypersomnolence have a range of options in addition to medications, to improve their health. If effective, this project will be tested in more people and may become a part of routine patient care. These dietary approaches have been shown to improve health and quality of life in people living with chronic pain, neurological conditions such as epilepsy and have been shown to be safe in these populations as well as people living with type one diabetes. This is a new area of research for people living with hypersomnolence.

Начало: 23.06.2025 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia University of Sydney NCT07006233

Набира участници Фаза 1

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Lymphoma Lymphoma, Non Hodgkin

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

Начало: 23.06.2025 Край: 01.11.2030 Възраст: от 18 г. Лечение

Australia, Canada, United States Treeline Biosciences, Inc. NCT07082803

Набира участници Фаза 3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Pulmonary Disease, Chronic Obstructive

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Начало: 23.06.2025 Край: 21.08.2029 Възраст: 40–80 г. Лечение

Argentina, Australia, Bulgaria +11 GlaxoSmithKline NCT06961214

Набира участници Фаза 2

A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

Moderate to Severe Acute Ischaemic Stroke Ischaemic Stroke

The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.

Начало: 20.06.2025 Край: 28.06.2026 Възраст: от 45 г. Лечение

Australia EIP Pharma Inc NCT06987643

Набира участници

Effect of Fasting Recommendations Among Patients Using GLP-1 Receptor Agonists

Residual Gastric Contents Pulmonary Aspiration of Gastric Contents

The aim of this randomised controlled trial is to determine the effect of a 24-hour clear liquid diet compared to standard fasting guidelines on the proportion of participants who present with increased residual gastric contents during their study visit. It also aims to determine the effect of a 24-hour clear liquid diet compared to standard fasting guidelines on: * Solid content or thick fluids * Patient-reported outcome measures (PROMs), including thirst, hunger, nausea, fatigue, and anxiety. * Compliance measures, including adherence with the intervention, time since last oral intake of solid foods, and time since last oral intake of clear liquids. We will enrol adults who are currently using any once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) medication. Participants will be allocated in a 1:1 ratio to follow a 24-hour clear liquid diet or standard fasting guidelines prior to attending a study visit where participants will undergo a blinded gastric ultrasound assessment.

Начало: 20.06.2025 Край: 09.02.2026 Възраст: от 18 г. Превенция

Australia St Vincent's Hospital Melbourne NCT06839248

Набира участници

Transscleral Selective Laser Trabeculoplasty Project

Glaucoma,Open-Angle Ocular Hypertension (OH)

The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty. Selective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors. Participants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.

Начало: 19.06.2025 Край: 01.11.2025 Възраст: от 18 г. Устройства

Australia Lumibird Medical (Quantel Medical, Ellex Medical, Optot NCT06833060

Набира участници Фаза 1

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Respiratory Syncytial Virus Vaccination Human Metapneumovirus Vaccination Parainfluenza Vaccination

This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.

Начало: 18.06.2025 Край: 30.06.2026 Възраст: 65–80 г. Превенция

Australia Clover Biopharmaceuticals AUS Pty NCT06984094

Набира участници Фаза 1

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

Overweight or Obesity

This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.

Начало: 18.06.2025 Край: 01.05.2026 Възраст: 18–60 г. Лечение

Australia Shanghai Minwei Biotechnology Co., Ltd NCT06938269

Набира участници Фаза 3

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Parkinsons Disease (PD)

Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

Начало: 17.06.2025 Край: 01.03.2032 Възраст: 45–75 г. Лечение

Australia, Canada, United States BlueRock Therapeutics NCT06944522

Набира участници Фаза 3

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Homozygous Familial Hypercholesterolemia

This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.

Начало: 17.06.2025 Край: 20.08.2027 Възраст: от 12 г. Лечение

Australia, Canada, Georgia +5 Arrowhead Pharmaceuticals NCT07037771

Набира участници Фаза 2

A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer

Colorectal Cancer

The aim of Neo-POLEM is to determine the rate of Major Pathological Response (MPR) of \

Начало: 16.06.2025 Край: 31.01.2029 Възраст: от 18 г. Лечение

Australia, United Kingdom University of Southampton NCT06692959

Набира участници Фаза 1

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.

Начало: 15.06.2025 Край: 15.03.2027 Възраст: от 18 г. Лечение

Australia Atridia Pty Ltd. NCT06830850

Набира участници Фаза 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

PIK3CA-Related Overgrowth Spectrum (PROS) Lymphatic Malformations Vascular Malformations PIK3CA Mutation +3

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.

Начало: 13.06.2025 Край: 01.10.2031 Възраст: от 2 г. Лечение

Australia, Belgium, Italy +3 Relay Therapeutics, Inc. NCT06789913

Набира участници Фаза 1

Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Lung Disease

This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.

Начало: 13.06.2025 Край: 01.12.2026 Възраст: 39–69 г. Лечение

Australia SMSbiotech NCT06986070

Набира участници Фаза 1

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.

Начало: 12.06.2025 Край: 30.12.2027 Възраст: от 18 г. Лечение

Australia Shenyang Sunshine Pharmaceutical Co., LTD. NCT07016490

Набира участници

Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours

Brain Tumours

The overall objective of this research is to investigate the clinical characteristics pre- and post-brain tumour resection with a focus on visual verticality disorder, and lateropulsion, including neuroimaging analysis, of a neurosurgical cohort of patients with brain tumours. This prospective observational cohort study will investigate clinical and neuroimaging characteristics and the relationship between lateropulsion and visual verticality disorder in patients pre- and post-brain tumour resection. Patients (aged 18-80 years, with a confirmed diagnosis of brain tumour and a neurosurgical pathway) will be enrolled from the state-wide Neurosurgery Service of Western Australia at Sir Charles Gairdner Hospital.

Начало: 12.06.2025 Край: 30.12.2025 Възраст: 18–80 г.

Australia The University of Western Australia NCT06951659

Набира участници

Brain Network Stimulation for Chronic Low Back Pain.

Chronic Low Back Pain (CLBP)

This study looks at the non-invasive brain stimulation technique in people with chronic low back pain to see: * How effective non-invasive brain stimulation is at improving pain intensity in people with chronic low back pain? * How safe non-invasive brain stimulation is and what side effects there may be? * What study participants think of the study procedures and of the non-invasive brain stimulation as a treatment technique for chronic low back pain. Participants will be assigned to receive either active brain stimulation group or sham stimulation group randomly. Participants will be required to attend a total of twelve treatment sessions (approximately 1-hour each, three sessions per week, for four consecutive weeks). Assessments will be done at baseline (in the week 0), immediately post-completion of the intervention (in the week 5), and at the follow-up of one-month (in the week 8), three-months (in the week 16) and six-months (in the week 28) post-completion of intervention.

Начало: 12.06.2025 Край: 01.01.2028 Възраст: 18–75 г. Лечение

New Zealand University of Otago NCT06902233

1 … 23 24 25 26 27 … 154